Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Drop in Short Interest

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 19,600 shares, a decline of 7.5% from the May 31st total of 21,200 shares. Based on an average trading volume of 10,200 shares, the days-to-cover ratio is currently 1.9 days. Currently, 0.4% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on APRE. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Aprea Therapeutics in a research note on Monday, June 24th. Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Aprea Therapeutics in a research note on Tuesday, May 14th.

Aprea Therapeutics Trading Up 1.8 %

Shares of APRE stock opened at $3.87 on Thursday. The company has a market capitalization of $21.01 million, a P/E ratio of -1.17 and a beta of 1.04. The business’s 50 day moving average is $4.77 and its two-hundred day moving average is $5.49. Aprea Therapeutics has a twelve month low of $2.78 and a twelve month high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.11. The firm had revenue of $0.38 million for the quarter. Aprea Therapeutics had a negative net margin of 1,317.82% and a negative return on equity of 56.78%. As a group, equities analysts predict that Aprea Therapeutics will post -2.57 earnings per share for the current fiscal year.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.